The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Use a concentration of 0.01 - 0.03 µg/ml. Predicted molecular weight: 21 kDa.
Use a concentration of 2.5 µg/ml. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.
Ras proteins bind GDP/GTP and possess intrinsic GTPase activity.
Involvement in disease
Defects in NRAS are a cause of juvenile myelomonocytic leukemia (JMML) [MIM:607785]. JMML is a pediatric myelodysplastic syndrome that constitutes approximately 30% of childhood cases of myelodysplastic syndrome (MDS) and 2% of leukemia. Defects in NRAS are the cause of Noonan syndrome type 6 (NS6) [MIM:613224]. A syndrome characterized by facial dysmorphic features such as hypertelorism, a downward eyeslant and low-set posteriorly rotated ears. Other features can include short stature, a short neck with webbing or redundancy of skin, cardiac anomalies, deafness, motor delay and variable intellectual deficits.
Belongs to the small GTPase superfamily. Ras family.
Palmitoylated by the ZDHHC9-GOLGA7 complex. A continuous cycle of de- and re-palmitoylation regulates rapid exchange between plasma membrane and Golgi.
Cell membrane. Golgi apparatus membrane. Shuttles between the plasma membrane and the Golgi apparatus.
ab118814, at 2.5 µg/ml, staining NRAS in formalin-fixed, paraffin-embedded Human Small Intestine tissue by Immunohistochemistry using a biotinylated anti-goat IgG secondary antibody, alkaline phosphatase-streptavidin and chromogen.
Western blot - Anti-NRAS antibody (ab118814)
Anti-NRAS antibody (ab118814) at 0.01 µg/ml + A431 lysate in RIPA buffer at 35 µg